We previously demonstrated that the BMI independently predicted the survival outcome of individuals with NSCLC expressing high PD‐L1 (PD‐L1 TPS ≥50%) who were treated with initial Pemb monotherapy; overweight individuals had prolonged survival, but not PFS, compared with underweight individuals.44 The gene discussed is CD274; the disease is non-small cell lung carcinoma.